Back to Directory
Spirea
East of England
Multivalent linker technologies for antibody-drug conjugate therapeutics
Spirea is a biopharmaceutical company developing antibody-drug conjugate technologies for targeted cancer treatment.
Its multivalent linker platform is designed to attach a wider range of drug payloads to antibodies while enabling higher payload loading and controlled delivery. Spirea conducts preclinical research on linker-payload chemistry and conjugate performance and collaborates with pharmaceutical partners on antibody-drug conjugate development, aiming to improve the delivery of therapeutic agents to diseased cells.